Navigation Links
Regulus Therapeutics Expands Worldwide Patent Coverage on microRNA-122 to Treat Hepatitis C Virus (HCV) Infection
Date:11/2/2011

stralia following issuances in Europe and the United States. This further exemplifies Regulus' leading intellectual property portfolio in the field of microRNA therapeutics. Recent clinical data in the field has demonstrated that inhibiting miR-122 with an oligonucleotide is safe, well tolerated, and able to reduce viral titers. That data, in combination with Regulus' data demonstrating potent inhibition with a proprietary anti-miR having favorable pharmacokinetic properties, supports the development of anti-miR-122 for the treatment of HCV in combination with other anti-virals," said Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive Officer of Regulus Therapeutics. "The HCV landscape has undergone a tremendous amount of transformation with the recent emergence of new direct-acting antivirals.  Anti-miR-122 is attractively positioned because it targets a host factor that is essential for viral replication and therefore may be resistant to viral mutation and escape."

miR-122 is a liver-expressed microRNA that has been shown to be a critical endogenous "host factor" for the replication of HCV, and anti-miRs targeting miR-122 have been shown to block HCV infection (Jopling et al. (2005) Science 309, 1577-81). In earlier work, scientists at Alnylam Pharmaceuticals and Isis Pharmaceuticals (Regulus' co-founders) demonstrated the ability to antagonize miR-122 in vivo using chemically modified single-stranded anti-miR oligonucleotides. Data from multiple preclinical studies have shown a robust HCV antiviral effect following inhibition of miR-122.  In February 2010, Regulus and GlaxoSmithKline entered into a new collaboration to develop and commercialize microRNA therapeutics targeting microRNA-122 for the treatment of hepatitis C infection.

Regulus is advancing multiple other microRNA therapeutic programs to the clinic in the areas of fibrosis, immuno-inflammatory disease, metabolic disease, and oncology.

'/>"/>
SOURCE Regulus Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Webinar Advisory: Regulus to Host Discussion About Potential of microRNA-33 as Target for Treatment of Atherosclerosis
2. Regulus Therapeutics to Present New Advancements in microRNA Therapeutics for Treatment of Metabolic Diseases and Cancer
3. Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board
4. Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33
5. Echo Therapeutics Announces Warrant Exercise by Its Largest Shareholder
6. Telik Announces Ezatiostat (Telintra®) Preclinical Presentation at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
7. Pearl Therapeutics Presents New Scientific Evidence Supporting Versatility of Its Novel Cosuspension MDI Platform
8. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
9. Pneumonia Therapeutics - Pipeline Assessment and Market Forecasts to 2018
10. Epilepsy Therapeutics - Pipeline Assessment and Market Forecasts to 2018
11. Osteoarthritis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 North America Gynecological Devices ... GlobalData,s new report, "North America Gynecological ... data on the North America Gynecological Devices market. ... dollars, volume (in units) and average prices (in ... Devices (Transcervical Sterilization Devices (Micro-inserts) and Mechanical Sterilization ...
(Date:9/17/2014)... NEW YORK , Sept. 17, 2014 ... significant growth during the last decade due ... environment, natural calamities and technological advancements. This ... strategies within various segments of the ambulance ... as transportation equipment, blood and hemorrhage control ...
(Date:9/17/2014)... 17, 2014  Decision Resources Group finds ... eligible for biologic therapy, only a proportion ... gastroenterologists cite patients, discomfort with biological therapy ... rates, followed by cost-related issues and payer ... biologics, Janssen Biotech,s Remicade and AbbVie,s Humira ...
Breaking Medicine Technology:North America Gynecological Devices Market Outlook to 2020 2North America Gynecological Devices Market Outlook to 2020 3Ambulance and Emergency Equipment: Global Markets 2Ambulance and Emergency Equipment: Global Markets 3Ambulance and Emergency Equipment: Global Markets 4The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 2The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 3
... 2012  Sensitech Inc., the global leader in cold ... Transport Association (IATA) has deemed Sensitech,s full range ... in compliance with the 53rd edition of the ... published by the United Nations.   The size and ...
... FRANCISCO, April 26, 2012 Onyx Pharmaceuticals, Inc. (Nasdaq: ... Food and Drug Administration,s (FDA) Oncologic Drugs Advisory Committee ... for carfilzomib for the treatment of patients with relapsed ... two prior therapies. ODAC will review carfilzomib at its ...
Cached Medicine Technology:Sensitech Inc. Products Receive Regulatory Compliance Approval from IATA 2Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma 2Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma 3
(Date:9/18/2014)... N-Zyme Scientifics LLC achieved a major developmental milestone ... mere 8 months after company startup. Its novel product ... enzyme used in the “Biologics” industry for discovery and ... pathology on Mass Spec devices. PRIME™ is being sold ... market (PNGase F PRIMETM). N-Zyme is currently evaluating ...
(Date:9/17/2014)... 18, 2014 The global ablation technologies ... 9.6% from 2014 to 2019. Although mature markets (such ... larger shares in the ablation technologies market in 2014, ... highest CAGR of 12.8% in the next five years.Factors ... infrastructure, growing number of hospitals and surgical centers, and ...
(Date:9/17/2014)... 18, 2014 iFitDress.com, a renowned wedding dress ... petite evening dresses . All these outfits are now ... discounted shipping costs. , “iFitDress.com is a professional company ... We are now busy selling our new collection of petite ... an order above $800 can get free shipping. All these ...
(Date:9/17/2014)... 2014 Mercy College is proud to welcome ... of Social and Behavioral Sciences. As dean, she ... the academic mission of the dynamic undergraduate and graduate programs ... honored to join Mercy College. During my first three ... campuses dedicated to the educational mission of the College. ...
(Date:9/17/2014)... Lake City, UT (PRWEB) September 17, 2014 ... Miss America 2015 Kira Kazantsev and ushered in ... need charitable support. As Miss America Organization’s official ... is welcoming Kazantsev as its newest National Goodwill ... her at member Children’s Miracle Network Hospitals across ...
Breaking Medicine News(10 mins):Health News:N-Zyme Scientifics Announces Successful Product Launch 2Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 2Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 3Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 4Health News:Elegant Petite Evening Dresses Introduced By Renowned Supplier iFitDress.com 2Health News:Mercy College Welcomes New Dean of the School of Social and Behavioral Sciences 2Health News:Miss America 2015 Kira Kazantsev Takes On Role as Children’s Miracle Network Hospitals National Goodwill Ambassador 2Health News:Miss America 2015 Kira Kazantsev Takes On Role as Children’s Miracle Network Hospitals National Goodwill Ambassador 3
... Sept. 20 Approximately 100,corporate pilots and ... earn,lifesaving certifications provided by the American Heart ... Safety Standdown in Wichita, Kan.,Oct. 22-25. ... event offers safety,training to the business aviation ...
... single dose of Otsukas investigational oral medication tolvaptan, ... in hemodynamics associated with a significant increase in ... (ADHF) who participated in the international trial the ... with HEart failure (ECLIPSE), presented at the late ...
... Inc.,(TSX: LOR; AMEX: LRP), a biopharmaceutical company specializing ... technologies for,the management of cancer, today announced that ... Vincent were elected to the Board of Directors ... 19, 2007. Dr. Burger has been,unanimously elected as ...
... A Florida pharmacy,owner and a Kentucky physician pleaded ... pharmacy business that generated more than,$126 million in ... Assistant Attorney General Alice S. Fisher of the ... the Southern District of,California announced today. Claude ...
... ... Zoo, Chicago, FAIRFAX, Va., Sept. 19 ... heavy vaginal,bleeding caused by uterine fibroids, noncancerous tumors that develop in,the muscular ... of Chicago, IL, and is a 46-year-old menopausal western lowland,gorilla. Doctors have ...
... Event to Take Place Friday February 8th, 2008, ... Inc. of Rancho Mirage, will host its first,annual Gala, ... A. Lopez, Director of Internal Medicine Specialists-Rancho,Mirage. The elegant ... Resort in Rancho Mirage and will begin at 6:00 ...
Cached Medicine News:Health News:MedAire to Provide Medical Training for Bombardier Safety Standdown 2Health News:MedAire to Provide Medical Training for Bombardier Safety Standdown 3Health News:ECLIPSE data on effects of Otsuka's investigational novel treatment, Tolvaptan 2Health News:Lorus Therapeutics announces election of three new Directors and appoints a new Chairman 2Health News:Lorus Therapeutics announces election of three new Directors and appoints a new Chairman 3Health News:Lorus Therapeutics announces election of three new Directors and appoints a new Chairman 4Health News:Doctor and Pharmacy Owner Plead Guilty in Internet Pharmacy Conspiracy 2Health News:Doctor and Pharmacy Owner Plead Guilty in Internet Pharmacy Conspiracy 3Health News:Gorilla Receives State-Of-The-Art Treatment for Uterine Fibroids from Interventional Radiologists 2Health News:Gorilla Receives State-Of-The-Art Treatment for Uterine Fibroids from Interventional Radiologists 3Health News:IMA South American Extravaganza Dinner to Honor Coachella Valley Doctor 2
... high-end microplate reader with outstanding sensitivity and ... Fluorescence Intensity - FRET , Fluorescence Polarization ... , Luminescence , , , ... reader with fastest read times. The ultimate ...
GENios Pro, TECANs advanced, multi-functional injector reader offers simultaneous reagent dispensing and detection for monitoring of fast kinetic reactions...
... Throughput Screening (UHTS), Analyst GT delivers ... for smooth transfer of assays into ... all the detection modalities of Analyst ... polarization, time-resolved fluorescence, luminescence, absorbance, as ...
... a fully automated microplate based multi-detection ... principles:, , Fluorescence Polarization , ... , High-Performance Luminescence (flash and glow) ... is designed for the widest possible ...
Medicine Products: